Report #2854805

Received Aug 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: CT
Recovered: Unknown
Vaccinated: Jun 27, 2025
Onset: Jun 27, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	2	946013	IM / LA

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

Had First Dose of ENGERIX 5/25/2025, Second Dose was HEPLISAV-B on 6/27/2025; Initial report received on 28-Jul-2025. A pharmacist reported that a 43-year-old male received ENGERIX-B for the first dose of hepatitis B immunization, and HEPLISAV-B (hepatitis B vaccine) for his second dose. No medical history or concomitant medications were reported. On 25-May-2025, the patient received dose 1 of a hepatitis B vaccine [ENGERIX-B (lot number, expiration date, NDC number, route, and site not available)]. On 27-Jun-2025, 34 days after receiving ENGERIX-B, the patient received dose 2 of a hepatitis B vaccine [HEPLISAV-B (lot number 946013, expiration date 31-Aug-2027, and NDC number 43528-003-05)] intramuscularly in the left deltoid. The patient has not had any HEPLISAV-B since then. No other side effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Other medications

Engerix b